<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346907</article-id>
      <article-id pub-id-type="pmc">3876014</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132388</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Blastic plasmacytoid dendritic cell neoplasm<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Neoplasia bl&#xE1;stica de c&#xE9;lulas dendr&#xED;ticas plasmocit&#xF3;ides</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lencastre</surname>
            <given-names>Andr&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cabete</surname>
            <given-names>Joana</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jo&#xE3;o</surname>
            <given-names>Alexandre</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Farinha</surname>
            <given-names>Pedro</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Gilda</given-names>
          </name>
          <xref ref-type="aff" rid="aff05">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lestre</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD - Resident Physician in Dermatovenereology - Dermatology Service,
Hospital de Santo Ant&#xF3;nio dos Capuchos, Centro Hospitalar de Lisboa Central, EPE -
Lisbon, Portugal.</aff>
      <aff id="aff02"><label>2</label> MD -Integrated Master's degree in Medicine - Resident Physician in
Dermatovenereology - Dermatology Service, Santo Ant&#xF3;nio dos Capuchos Hospital, Hospital
Center of Central Lisbon, EPE - Lisbon, Portugal.</aff>
      <aff id="aff03"><label>3</label> MD - Eventual Assistant of Dermatovenereology - Dermatology Service,
Hospital de Santo Ant&#xF3;nio dos Capuchos, Centro Hospitalar de Lisboa Central, EPE -
Lisbon, Portugal.</aff>
      <aff id="aff04"><label>4</label> MD - Hospital Assistant of Pathology Department - Service of
Pathological Anatomy, Hospital de Santo Ant&#xF3;nio dos Capuchos, Centro Hospitalar de
Lisboa Central, EPE - Lisbon, Portugal.</aff>
      <aff id="aff05"><label>5</label> MD - Eventual Assistant of Hematology - Hematology Service, Hospital de
Santo Ant&#xF3;nio dos Capuchos, Centro Hospitalar de Lisboa Central, EPE - Lisbon,
Portugal.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Andr&#xE9; Lencastre, Alameda de Santo Ant&#xF3;nio dos Capuchos,
1169-050 - Lisboa - Portugal. E-mail: <email>lencastre.derm@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>158</fpage>
      <lpage>161</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive hematodermic
neoplasia with frequent cutaneous involvement and leukemic dissemination. We report
the case of a 76-year-old man with a 2 month history of violaceous nodules and a
tumor with stony consistency, located on the head, and mandibular, cervical and
supraclavicular lymphadenopathies. Multiple thoracic and abdominal adenopathies were
identified on computerized tomography. Flow cytometry analysis of the skin, lymph
node and bone marrow biopsies demonstrated the presence of plasmocytoid dendritic
cell neoplastic precursor cells (CD4+, CD45+, CD56+ and CD123+ phenotype). After
initial clinical and laboratorial complete remission with chemotherapy, the patient
died due to relapse of the disease associated with the appearance of a cervical mass
with medullary compromise.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A neoplasia bl&#xE1;stica de c&#xE9;lulas dendr&#xED;ticas plasmocit&#xF3;ides &#xE9; uma neoplasia
hematod&#xE9;rmica rara, agressiva, com frequente envolvimento cut&#xE2;neo e dissemina&#xE7;&#xE3;o
leuc&#xEA;mica. Relatamos o caso de um homem de 76 anos com quadro cl&#xED;nico com 2 meses de
evolu&#xE7;&#xE3;o caracterizado por n&#xF3;dulos e tumor de tonalidade viol&#xE1;cea, de consist&#xEA;ncia
p&#xE9;trea, localizados na cabe&#xE7;a, e linfadenopatias mandibular, cervicais e
supraclaviculares. Identificaram-se m&#xFA;ltiplas adenopatias tor&#xE1;cicas e abdominais em
tomografia computorizada. A an&#xE1;lise por citometria de fluxo de bi&#xF3;psias cut&#xE2;nea,
ganglionar e &#xF3;ssea demonstrou a presen&#xE7;a de precursores neopl&#xE1;sicos das c&#xE9;lulas
dendr&#xED;ticas plasmocit&#xF3;ides (fen&#xF3;tipo CD4+, CD45+, CD56+ e CD123+). Ap&#xF3;s remiss&#xE3;o
cl&#xED;nica e laboratorial completa inicial com quimioterapia, veio a falecer por reca&#xED;da
da doen&#xE7;a associada ao aparecimento de massa cervical com compromisso medular.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Antigens, CD4</kwd>
        <kwd>Antigens, CD56</kwd>
        <kwd>Dendritic cells</kwd>
        <kwd>Leukemia</kwd>
        <kwd>Leukemic infiltration</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) was originally recognized in 1994,
but the subsequent lack of knowledge concerning its histogenesis led to a succession of
different designations such as agranular CD4+ natural killer cell leukemia, blastic
natural killer leukemia/lymphoma, agranular CD4+CD56+ hematodermic neoplasm or
tumor.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r05">5</xref></sup> BPDCN is characterized by predominant cutaneous
involvement with concomitant or ensuing spread to the bone marrow and peripheral blood.
It has a very aggressive clinical behavior with short survivals.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 76-year-old man was referred for evaluation of various cutaneous lesions. He had a
prior history of total prostatectomy due to prostate adenocarcinoma 6 years before the
current observation and myelodys plastic syndrome (MDS) presenting with neutropenia
followed-up in hematology for 4 years. His neutropenia had been extensively studied
through imaging studies and bone marrow aspirate and biopsy. MDS of the refractory
cytopenia with multilineage dysplasia subtype was diagnosed and an expectant approach
with careful observation was undertaken. </p>
      <p>Two months before referral, he progressively developed multiple violaceous plaques and
nodules on the face and scalp. He denied any constitutional symptoms and mentioned just
a prior episode of minor head trauma. The physical examination revealed multiple
well-demarcated, indurated plaques and nodules scattered throughout the right
frontotemporal and biparietal areas as well as a 7 cm wide tumor in the anterior
interparietal area (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). Several mandibular, cervical and supraclavicular
lymphadenopathies were noted. He was otherwise well, which contrasted with the severity
of the cutaneous findings. Laboratory results revealed hemoglobin 127 g/L, white blood
cell count 6.0 x 10<sup>9</sup> /L with 55% lymphocytes; an additional decrease in
neutrophils (0.7 x 10<sup>9</sup> /L) and platelet count of 241 x 10<sup>9</sup> /L were
noted. Lactate dehydrogenase was elevated at 1139 U/L. Chest radiography was
unremarkable. Thoracoabdomino-pelvic computerized tomography revealed enlargement of
several mediastinal, axillary, celiac, retroperitoneal, obturator and inguinofemoral
lymph nodes (some larger than 25 mm). </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Violaceous, stony tumor in the anterior interparietal region</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Multiple bilateral nodules and plaques in the parietal areas</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g02"/>
      </fig>
      <p>Histology of skin and 2 cervical lymph nodes revealed a monomorphous, non-epidermotropic
diffuse infiltration of small-to-medium sized cells with pleomorphic nuclei (<xref ref-type="fig" rid="f03">Figure 3</xref>) in the skin. This dense infiltrate effaced
the nodal architecture and was located in the dermis and hypodermis, separated from the
epidermis by a grenz zone. </p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Histology of the interparietal tumor revealed compact, dermal and hypodermal
infiltrate of non-epidermotropic monomorphous cells and blood extravasation
(H&amp;E'100)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g03"/>
      </fig>
      <p>By immunohistochemistry, the cells coexpressed CD4, CD43, CD45 CD56, showed partial
positivity for CD68 (<xref ref-type="fig" rid="f04">Figures 4</xref> and <xref ref-type="fig" rid="f05">5</xref>) and were negative for CD3, CD5, CD8, CD20, CD30,
CD34, CD38, CD117, TDT, myeloperoxidase, light IgG chains and PAX5 (<xref ref-type="fig" rid="f06">Figure 6</xref>). The proliferative index (Ki-67) was high, approximately
60%. </p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Diffuse infiltration by strongly positive tumor cells highlighting grenz zone (CD4
&#xD7;200)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Diffuse infiltration by positive tumor cells (CD56 &#xD7;200)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g05"/>
      </fig>
      <fig id="f06" orientation="portrait" position="float">
        <label>FIGURE 6</label>
        <caption>
          <p>Diffuse infiltration by positive tumor cells (CD56 &#xD7;200)</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0158-g06"/>
      </fig>
      <p>Bone marrow biopsy showed a markedly hypercellular marrow, with CD4+, CD43+,CD45+,
CD56+, CD123+ and HLA-DR+ small blast cells accounting for 80% of cellularity. No
expressions of other T or B cell lineage were observed. </p>
      <p>Based on clinical and laboratory findings, the patient was diagnosed with BPDCN with
extensive cutaneous, nodal and bone marrow involvement. </p>
      <p>Six cycles of CHOP (cyclophosphamide, adryamicine, vincristine, and prednisolone) were
prescribed, with remission. Only post-therapy inflammatory reactive lesions remained on
the face and scalp. </p>
      <p>Two months later, the disease relapsed. Left-sided brachial monoparesis developed and a
paravertebral cervical (C2-C3) mass with medullary compromise through the intervertebral
foramen was detected on magnetic resonance imaging. The patient was hospitalized in a
status of rapid progression of the disease, with enlargement of the cervical mass,
hyperleukocytosis (&gt; 100.000/ml), mental status deterioration and died 7 months after
the diagnosis (9 months after onset of the first clinical symptoms). </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The origin of BPDCN presumably lies in a hematopoietic precursor of plasmacytoid
dendritic cells (DCs) of yet undefined lymphoid versus myeloid lineage.<sup><xref ref-type="bibr" rid="r06">6</xref>-<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>It is a rare disease, typically manifesting in middle-aged or elderly men (although
pediatric cases have been reported).<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
The clinical picture and progression of BPDCN consist of two main patterns. In 90% of
cases, there is an indolent installation of cutaneous lesions followed later by
dissemination, whereas in the remaining 10% it presents as advanced leukemia with
systemic involvement from the start. Previous existence of MDS has also been reported in
a few cases.<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>The presence of multiple skin lesions is a feature of both patterns described, found in
over 90% of BPDCN cases.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup> Isolated skin lesions are also detected
in over half of cases.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> Skin
involvement may display a nodular or a patch and bruise-like lesion presentation, with a
thicker neoplastic infiltrate in the former and a perivascular arrangement in the
latter.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> In both cases, a
diffuse and monomorphous dermal infiltrate of medium-sized cells, with an obvious
blastic morphology and epidermal sparing is reported.<sup><xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <p>The diagnosis requires the demonstration of CD4 and CD56, together with markers more
restricted to plasmacytoid dendritic cells (such as CD123) and negativity for lymphoid,
NK and myeloid lineage-associated antigens.<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>In our patient's bone marrow flow cytometry, cells were CD4+, CD45+, CD56+ and CD123+
and lacked lineage-specific antigens. This phenotype, albeit with specific isoform
CD45RA positivity, renders it highly specific, as published.<sup><xref ref-type="bibr" rid="r10">10</xref></sup>
</p>
      <p>Researchers debate whether tumor cells are originally sited in the bone marrow or skin.
Unresolved questions remain regarding its histogenesis and aggressive clinical
presentation that commonly affects both sites either consecutively or simultaneously.
Furthermore, the existence of rapidly disseminating disease cases and those with
primarily cutaneous disease and indolent progression raise questions to whether this
represents two stages of a disease spectrum or 2 different CD4+CD56+
malignancies.<sup><xref ref-type="bibr" rid="r06">6</xref></sup> Cutaneous tropism
of blast cells may explain frequent skin localization.<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>BPDCN has an aggressive clinical behavior despite an initial apparent indolence. The
median survival is approximately 12-14 months. </p>
      <p>Cognizant of our patient's age, CHOP chemotherapy was undertaken. The patient initially
responded favorably, as described in the literature.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup> As also reported, he had
a fast and aggressive relapse and died in a state of hyperleukocytosis (&gt; 100 x
10<sup>9</sup> /L) with a symptomatic central nervous system lesion, deemed secondary
to his BPDCN. </p>
      <p>Currently, there is no apparent consensus for the optimal treatment of BPDCN. Intensive
therapy for acute leukemia increases the rate of sustained complete remission. However,
only myeloablative treatment with allogenic bone marrow transplantation within the first
remission has resulted in a better chance of longer survival.<sup><xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at the Hospital de Santo Ant&#xF3;nio dos Capuchos, Centro Hospitalar de
Lisboa Central, EPE - Lisbon, Portugal.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Facchetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Petrella</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <chapter-title>Blastic plasmacytoid dendritic cells neoplasm</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Swerdlow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vardiman</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <source>WHO classification of Tumours of Haematopoietic and Lymphoid Tissues</source>
          <edition>4th ed</edition>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>International Agency for Research on Cancer</publisher-name>
          <year>2008</year>
          <fpage>145</fpage>
          <lpage>147</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adachi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takekawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hinoda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Imai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>High expression of CD56 (N-CAM) in a patient with cutaneous
CD4-positive lymphoma</article-title>
          <source>Am J Hematol</source>
          <year>1994</year>
          <volume>47</volume>
          <fpage>278</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="pmid">7526680</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petrella</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bagot</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Beylot-Barry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vergier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Delaunay</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic
Neoplasms)</article-title>
          <source>Am J Clin Pathol</source>
          <year>2005</year>
          <volume>123</volume>
          <fpage>662</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="pmid">15981806</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Facchetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ungari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marocolo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lonardi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vermi</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Blastic plasmacytoid dendritic cell neoplasm</article-title>
          <source>Haematol Meet Rep</source>
          <year>2009</year>
          <volume>3</volume>
          <fpage>1</fpage>
          <lpage>3</lpage>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanches</surname>
              <given-names>J</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Moricz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Festa Neto</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Lymphoproliferative processes of the skin: part 2 - cutaneous T-cell
and NK-cell lymphomas</article-title>
          <source>An Bras Dermatol</source>
          <year>2006</year>
          <volume>81</volume>
          <fpage>7</fpage>
          <lpage>25</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feuillard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Valensi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maynadi&#xE9;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gressin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chaperot</surname>
              <given-names>L</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Clinical and biological features of CD4+ CD56+
malignancies</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>1556</fpage>
          <lpage>1563</lpage>
          <pub-id pub-id-type="pmid">11861268</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petrella</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Comeau</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Maynadi&#xE9;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Couillault</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>De Muret</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Maliszewski</surname>
              <given-names>CR</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell lymphoma)
originates from a population of CD56+ precursor cells related to plasmocytoid
monocytes</article-title>
          <source>Am J Surg Pathol</source>
          <year>2002</year>
          <volume>26</volume>
          <fpage>852</fpage>
          <lpage>862</lpage>
          <pub-id pub-id-type="pmid">12131152</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pi&#xF1;a-Oviedo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Herrera-Medina</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Coronado</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Del Valle</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ortiz-Hidalgo</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review
of the concept of an uncommon tumor originated in plasmacytoid dendritic cells
expressing CD123 (IL-3 receptor alpha)</article-title>
          <source>Appl Immunohistochem Mol Morphol</source>
          <year>2007</year>
          <volume>15</volume>
          <fpage>481</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="pmid">18091395</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petrella</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dalac</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Maynadi&#xE9;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mugneret</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thomine</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Courville</surname>
              <given-names>P</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity?
Groupe Fran&#xE7;ais d'Etude des Lymphomes Cutan&#xE9;s (GFELC)</article-title>
          <source>Am J Surg Pathol</source>
          <year>1999</year>
          <volume>23</volume>
          <fpage>137</fpage>
          <lpage>146</lpage>
          <pub-id pub-id-type="pmid">9989839</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trimoreau</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Donnard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Turlure</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gachard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bordessoule</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Feuillard</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The CD4+ CD56+ CD116- CD123+ CD45RA+ CD45RO- profile is specific of
DC2 malignancies</article-title>
          <source>Haematologica</source>
          <year>2003</year>
          <volume>88</volume>
          <elocation-id/>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
